JPH11504941A - タイプii糖尿病のピコリン酸クロム高用量治療 - Google Patents
タイプii糖尿病のピコリン酸クロム高用量治療Info
- Publication number
- JPH11504941A JPH11504941A JP8534219A JP53421996A JPH11504941A JP H11504941 A JPH11504941 A JP H11504941A JP 8534219 A JP8534219 A JP 8534219A JP 53421996 A JP53421996 A JP 53421996A JP H11504941 A JPH11504941 A JP H11504941A
- Authority
- JP
- Japan
- Prior art keywords
- chromium
- tripicolinate
- diabetes
- chromium tripicolinate
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.必要とする人に合成トリピコリン酸クロムとしてクロムを1日当り約1, 000−10,000μg投与することからなる人の高血糖を減少し、血清グル コールの濃度を安定化させる方法。 2.合成トリピコリン酸クロムとしてクロムを1日当り約1,000−5,0 00μg投与することからなる請求項1記載の方法。 3.前記トリピコリン酸クロムが薬学的に許容しうる担体中にある、請求項1 記載の方法。 4.前記トリピコリン酸クロムが経口的に投与される、請求項3記載の方法。 5.前記トリピコリン酸クロムが非経口的に投与される、請求項3記載の方法 。 6.必要とする人の高血糖の治療および/または血清グルコース濃度の安定化 のための、各用量が約1,000−約10,000μgのクロムを有する、単位 用量形の合成トリピコリン酸クロム。 7.各用量が約1,000−約5,000μgのクロムを含む、請求項6記載 のトリピコリン酸クロム。 8.経口投与に適した形の請求項6または7記載のトリピコリン酸クロム。 9.非経口投与に適した形の請求項6または7記載のトリピコリン酸クロム。 10.薬学的に許容しうる担体中の請求項6または7記載のトリピコリン酸クロ ム。 11.必要とする人の高血糖の治療および/または血清グルコース濃度の安定化 のための医薬の調製における、各用量が約1,000−10,000μgのクロ ムを有する、単位用量形の合成トリピコリン酸クロムの使用。 12.各用量が約1,000−5,000μgのクロムを含む、請求項11記載 の使用。 13.前記トリピコリン酸クロムが経口投与に適する形にある、請求項11また は12記載の使用。 14.前記トリピコリン酸クロムが非経口投与に適する形にある、請求項11ま たは12記載の使用。 15.前記トリピコリン酸クロムが薬学的に許容しうる担体中に提供される、請 求項11または12記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/440,362 US6329361B1 (en) | 1995-05-12 | 1995-05-12 | High-dose chromic picolinate treatment of type II diabetes |
US08/440,362 | 1995-05-12 | ||
PCT/US1996/006493 WO1996035421A1 (en) | 1995-05-12 | 1996-05-08 | High-dose chromic tripicolinate for the treatment of type ii diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11504941A true JPH11504941A (ja) | 1999-05-11 |
JP3699124B2 JP3699124B2 (ja) | 2005-09-28 |
Family
ID=23748461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53421996A Expired - Lifetime JP3699124B2 (ja) | 1995-05-12 | 1996-05-08 | タイプii糖尿病のピコリン酸クロム高用量治療 |
Country Status (15)
Country | Link |
---|---|
US (1) | US6329361B1 (ja) |
EP (1) | EP0825861B1 (ja) |
JP (1) | JP3699124B2 (ja) |
AR (1) | AR004486A1 (ja) |
AT (1) | ATE227127T1 (ja) |
AU (1) | AU5733796A (ja) |
BR (1) | BR9608835A (ja) |
DE (1) | DE69624699T2 (ja) |
DK (1) | DK0825861T3 (ja) |
ES (1) | ES2183952T3 (ja) |
IL (1) | IL118222A (ja) |
PT (1) | PT825861E (ja) |
RU (1) | RU2195934C2 (ja) |
WO (1) | WO1996035421A1 (ja) |
ZA (1) | ZA963735B (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962030A (en) | 1997-03-07 | 1999-10-05 | Akesis Pharmaceuticals, Inc. | Dietary supplement and method of treatment for diabetic control |
CN1273531A (zh) * | 1997-08-08 | 2000-11-15 | 营养21 | 用铬/生物素治疗ⅱ型糖尿病 |
US5789401A (en) * | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
EP0925790A1 (en) * | 1997-12-17 | 1999-06-30 | Kartar Dr. Lalvani | Vitamin and mineral combinations for the treatment of syndrome X and non-insulin dependent diabetes (NIDDM) |
US5932258A (en) * | 1998-04-06 | 1999-08-03 | The Iams Company | Composition and process for improving glucose metabolism in companion animals |
US5948772A (en) | 1998-08-28 | 1999-09-07 | Ambi Inc. | Chromium picolinate compositions and uses thereof |
US6143301A (en) | 1998-08-28 | 2000-11-07 | Ambi Inc. | Chromium picolinate compositions and uses thereof |
US5905075A (en) * | 1998-08-28 | 1999-05-18 | Ambi Inc. | Chromium nicotinate compositions and uses thereof |
US6376549B1 (en) | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
WO2000015211A2 (en) | 1998-09-17 | 2000-03-23 | Akesis Pharmaceuticals, Inc. | Compositions of chromium or vanadium with antidiabetics for glucose metabolism disorders |
EP1357977B1 (en) | 2000-09-21 | 2004-07-21 | Nutrition 21, Inc. | Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia |
WO2003090671A2 (en) * | 2002-04-23 | 2003-11-06 | Nutrition 21, Inc. | Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
ATE476188T1 (de) * | 2002-05-14 | 2010-08-15 | Nipro Corp | Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie |
US6831077B2 (en) * | 2002-07-25 | 2004-12-14 | Comprehensive Neuroscience, Inc. | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
US20050019435A1 (en) * | 2003-07-21 | 2005-01-27 | Jeffrey Young | Method of treating non-insulin dependent diabetes mellitus and related complications |
US20050085454A1 (en) * | 2003-10-16 | 2005-04-21 | Natreon Inc. | Phenolic antioxidant-chromium complexes for treatment or prevention of type 2 diabetes or glucose intolerance |
CA3021932C (en) * | 2007-01-31 | 2020-12-15 | Jds Therapeutics, Llc | Use of chromium histidinate for treatment of cardiometabolic disorders |
CA2681158C (en) | 2007-03-13 | 2018-09-18 | Nutrition 21, Inc. | Methods and compositions for the sustained release of chromium |
WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
WO2011002939A1 (en) | 2009-07-01 | 2011-01-06 | Nutrition 21, Inc. | Chromium complexes as enhancers of brain glucose transporters |
CN105749253A (zh) | 2011-03-01 | 2016-07-13 | Jds治疗有限公司 | 用于预防和治疗糖尿病、低血糖症及相关病症的胰岛素和铬组合物 |
WO2016130981A1 (en) | 2015-02-13 | 2016-08-18 | Mars, Incorporated | Pet food feeding system |
AU2017217466A1 (en) | 2016-02-11 | 2018-08-23 | Nutrition 21, Llc | Chromium containing compositions for improving health and fitness |
US10820617B1 (en) | 2018-03-29 | 2020-11-03 | Government Of The United States, As Represented By The Secretary Of The Air Force | All inclusive electrolytes, vitamins, and protein powder training supplement |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4315927A (en) * | 1980-08-08 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Dietary supplementation with essential metal picolinates |
US5087623A (en) * | 1988-05-31 | 1992-02-11 | Nitrition 21 | Chromic picolinate treatment |
US5164384A (en) | 1991-06-19 | 1992-11-17 | Metagenics, Inc. | Anabolic mineral formula |
-
1995
- 1995-05-12 US US08/440,362 patent/US6329361B1/en not_active Expired - Lifetime
-
1996
- 1996-05-08 BR BR9608835-4A patent/BR9608835A/pt not_active IP Right Cessation
- 1996-05-08 ES ES96915595T patent/ES2183952T3/es not_active Expired - Lifetime
- 1996-05-08 DE DE69624699T patent/DE69624699T2/de not_active Expired - Fee Related
- 1996-05-08 AT AT96915595T patent/ATE227127T1/de not_active IP Right Cessation
- 1996-05-08 DK DK96915595T patent/DK0825861T3/da active
- 1996-05-08 RU RU97120726/14A patent/RU2195934C2/ru not_active IP Right Cessation
- 1996-05-08 EP EP96915595A patent/EP0825861B1/en not_active Expired - Lifetime
- 1996-05-08 JP JP53421996A patent/JP3699124B2/ja not_active Expired - Lifetime
- 1996-05-08 WO PCT/US1996/006493 patent/WO1996035421A1/en active IP Right Grant
- 1996-05-08 PT PT96915595T patent/PT825861E/pt unknown
- 1996-05-08 AU AU57337/96A patent/AU5733796A/en not_active Abandoned
- 1996-05-10 AR ARP960102526A patent/AR004486A1/es unknown
- 1996-05-10 IL IL11822296A patent/IL118222A/xx not_active IP Right Cessation
- 1996-05-10 ZA ZA963735A patent/ZA963735B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AR004486A1 (es) | 1998-12-16 |
JP3699124B2 (ja) | 2005-09-28 |
DK0825861T3 (da) | 2003-03-03 |
AU5733796A (en) | 1996-11-29 |
BR9608835A (pt) | 1999-12-07 |
RU2195934C2 (ru) | 2003-01-10 |
EP0825861B1 (en) | 2002-11-06 |
US6329361B1 (en) | 2001-12-11 |
ATE227127T1 (de) | 2002-11-15 |
DE69624699T2 (de) | 2003-03-20 |
IL118222A0 (en) | 1996-09-12 |
IL118222A (en) | 2000-06-01 |
ZA963735B (en) | 1997-01-09 |
MX9708628A (es) | 1998-06-28 |
EP0825861A1 (en) | 1998-03-04 |
ES2183952T3 (es) | 2003-04-01 |
PT825861E (pt) | 2003-03-31 |
DE69624699D1 (de) | 2002-12-12 |
WO1996035421A1 (en) | 1996-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3699124B2 (ja) | タイプii糖尿病のピコリン酸クロム高用量治療 | |
US5789401A (en) | High-dose chromium/biotin treatment of type II diabetes | |
US5157022A (en) | Method for reducing blood cholesterol using arginine | |
JP5690261B2 (ja) | β−ヒドロキシ−β−メチル酪酸および少なくとも1つのアミノ酸を含む組成物および使用法 | |
JPH04504847A (ja) | インスリン抵抗性糖尿病のための食事用補添物 | |
MXPA04003233A (es) | Metodo y composicion para prevenir o reducir los sintomas del sindrome de resistencia a la insulina. | |
USRE39480E1 (en) | Chromium/biotin treatment of type II diabetes | |
WO1995017889A1 (fr) | Composition therapeutique utile pour traiter l'hyperparathyroidie d'un patient en dialyse artificielle | |
WO2004017916A2 (en) | Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition | |
JP3622985B2 (ja) | マグネシウム吸収を高め、アテローム性動脈硬化症を防ぐ方法 | |
KR20070086007A (ko) | 당뇨병의 치료를 위한 의약 조성물 | |
JPS6299323A (ja) | 高脂血症剤 | |
EP0679394B1 (en) | Menatetronome derivative as antiarteriosclerotic agent | |
AU2002302012B2 (en) | Chromim/biotin treatment of type II diabetes | |
WO2000051594A1 (en) | Use of succinic acid or salts thereof and method of treating insulin resistance | |
EP0611570A1 (en) | Use of chromic tripicolinate in the treatment of obese diabetic patients | |
MXPA97008628A (en) | Treatment of type ii diabetes with high doses of picolinato cróm | |
EP0445920A2 (en) | Use of ethoxy phenoxy acetic acid derivatives against diabetes | |
CN1189776A (zh) | 大剂量给药用于治疗ⅱ型糖尿病的三吡啶甲酸铬 | |
JPS6232726B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050307 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050607 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050707 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080715 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090715 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090715 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100715 Year of fee payment: 5 |